Praxis Precision Medicines, Inc. (PRAX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity.
Is Praxis Precision Medicines, Inc. stock overvalued or undervalued in 2026?
As of October 30, 2026, Praxis Precision Medicines, Inc. (PRAX) trades at $285.93 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Praxis Precision Medicines, Inc.
Market cap $8B · 52 weeks $164 – $386 (26 % below the high) · P/E no earnings · Dividend none · Next earnings November 9, 2026 · expected EPS -$3.54 · Closing price, Oct 30 · accounts published Aug 6.
- Valuation: P/E — (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 4 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 0.0 %, fails.
- Market cap / Cash 10.7×, fails.
- Cash Runway 29 months, passes.
- Total Debt 0.0×, passes.
- Annual cash burn $11.07, info.
Against its peers (reference peers) — Praxis Precision Medicines, Inc.: P/E —; EV/EBITDA —; ROIC -28.2 %; $8.0B. Neurocrine Biosciences, Inc. (P/E 21.4×; EV/EBITDA 16.2×; ROIC 13.2 %; $14.9B), Acadia Pharmaceuticals Inc. (P/E 9.3×; EV/EBITDA 27.9×; ROIC 6.2 %; $3.5B), Supernus Pharmaceuticals, Inc. (P/E —; EV/EBITDA 35.8×; ROIC -2.7 %; $2.4B).
Profitability
| Return on Equity | -34.15% |
| Return on Invested Capital | -28.18% |
| Return on Assets | -24.40% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 15.73 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 64.44 |
Price Performance
| 1 month | -3.24% |
| 3 months | -7.79% |
| Year-to-date | -2.99% |
| 1 year | +43.86% |
| 3 years | +1601.96% |
| 5 years | -13.24% |
Related companies: NBIX · AXSM · XENE · ACAD · DNLI · SUPN
Explore sector: Healthcare · Biotechnology
More sections of PRAX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks